Inhibitor Therapeutics, Inc. (INTI) reported a net loss of $3.3 million for the fiscal year ending December 31, 2025, compared to a loss of $3.4 million in the previous year. The company did not generate any revenue during this period, consistent with its status as a pre-revenue pharmaceutical development firm. Research and development expenses slightly decreased to $1.7 million from $1.8 million, while general and administrative expenses also saw a decline from $1.9 million to approximately $1.7 million. The company’s interest income fell to $0.1 million from $0.3 million, reflecting lower cash balances.
The company has undergone significant changes since settling litigation in late 2022, which had previously hindered its operations. In December 2023, INTI entered into an Exclusive License Agreement with Johns Hopkins University, acquiring rights to a patent related to angiogenesis inhibitors, which supports its focus on developing itraconazole for treating basal cell carcinoma nevus syndrome (BCCNS). This strategic move is part of a broader effort to enhance its intellectual property portfolio and advance its clinical programs.
Operationally, INTI is currently focused on its lead program involving itraconazole, an FDA-approved antifungal, repurposed for chronic management of BCCNS. The company has engaged Avior Bio, Inc. to develop a proprietary formulation of itraconazole, which is expected to improve bioavailability and support its clinical development. The company reported a per-lesion objective response rate of 57.7% in its Phase IIb clinical study, with a patient-level disease control rate of 97.4%. INTI is also preparing for a Type C meeting with the FDA, expected to provide guidance on its development pathway.
As of the end of 2025, INTI had two full-time employees and six part-time employees, reflecting a lean operational structure. The company is actively seeking to expand its workforce and capabilities as it progresses through regulatory development. The company’s liquidity remains a concern, with negative operating cash flows of $3.2 million for the year. To address this, INTI has entered a securities purchase agreement to raise $3 million, which it plans to use for working capital and general corporate purposes.
Looking ahead, INTI's management acknowledges the challenges of continuing as a going concern without additional funding. The company is exploring various financing strategies, including public or private sales of equity or debt securities. While the recent licensing agreement and ongoing clinical developments present opportunities for growth, the company remains subject to significant risks, including the need for FDA approval and market acceptance of its product candidates.
About Inhibitor Therapeutics, Inc.
Inhibitor Therapeutics, Inc. is a pharmaceutical development company focused on repurposing approved drugs, particularly itraconazole, for cancer treatment. It targets cancers such as basal cell carcinoma, prostate, and lung cancers by developing Hedgehog pathway inhibitors. The company advances clinical research, secures intellectual property, and seeks FDA designations to expedite approvals, aiming for market exclusivity and strategic partnerships in oncology therapeutics.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.